Non-Hodgkin's lymphomas: clinical governance issues.
Every patient in every part of the world has the right to expect the best possible quality of care from health care providers. Non-Hodgkin's lymphomas (NHL) are an extremely heterogeneous group of conditions which require important decisions to be taken at many points along the treatment pathway. To get this right every time requires that high-quality standards are instituted and adhered to, so that the best possible outcome is achieved. In the past this has not always been the case because of the failure of clinicians sometimes to adhere to an optimal management plan. In 1995, the UK government commissioned an inquiry into the running of cancer services in the United Kingdom, which culminated in a series of recommendations to improve them. Subsequently, these recommendations were implemented as objectives of the NHS Cancer Plan which is the framework by which the UK government wishes to improve cancer services. Concurrently another general concept has emerged which is designed to ensure that the highest quality standards may be achieved for all patients across the whole National Health Service (NHS). This concept, termed 'clinical governance', brings together a corporate responsibility of all health care workers to deliver high quality standards, in the hope that this will translate into better long-term survival of patients with malignant disease. This chapter focuses on the issues surrounding clinical governance and how the principles of this concept relate to non-Hodgkin's lymphomas.
Fields
P A
PA
Department of Haematology, University College Hospital, Grafton Way, London WCIE 6DB, UK.
Goldstone
A H
AH
D006801:Humans; D033183:Interdisciplinary Communication; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000628:therapy*; D009313:National Health Programs; D011787:Quality of Health Care / Q000941:ethics / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D006113:United Kingdom